Expertise in
8
conditions

Mark Guttman

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Mark Guttman practices in Toronto, Canada. Mr. Guttman is highly rated in 8 conditions, according to our data. His top areas of expertise are Huntington Disease, Movement Disorders, Chorea, and Parkinson's Disease.

His clinical research consists of co-authoring 37 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada
Markham, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Enrollment Status: Recruiting
Publish Date: May 31, 2025
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: February 28, 2024
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
Enrollment Status: Terminated
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: WVE-120102
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
Enrollment Status: Terminated
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: WVE-120101
Study Phase: Phase 1/Phase 2
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
Enrollment Status: Completed
Publish Date: August 08, 2017
Intervention Type: Behavioral
View 3 Less Clinical Trials

37 Total Publications

Atypical Presentations of Huntington Disease-like 2 in South African Individuals.
Atypical Presentations of Huntington Disease-like 2 in South African Individuals.
Journal: Movement disorders clinical practice
Published: October 23, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guttman's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile